David Mauro named chief medical officer and VP of Advaxis Inc.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DAVID MAURO was named as executive vice president and chief medical officer of Advaxis Inc.

Mauro will oversee the company’s clinical immuno-oncology programs. He most recently served as executive director and section head of Oncology Clinical Development at Merck & Co., where he was involved in oversight and implementation of multiple programs within the oncology portfolio, including its recently approved PD-1 inhibitor, Keytruda (pembrolizumab).

Prior to joining Merck, Mauro was director at Bristol-Myers Squibb, where his responsibilities included Erbitux (cetuximab) and Oncology Early Development.

During his career, Mauro has participated in multiple FDA submissions and approvals, including three successful new drug applications for Erbitux, Sprycel (dasatinib) and Sylatron (peginterferon alfa-2b), and two PMA filings for EGFR PharmDx and KRAS Companion Diagnostics.

YOU MAY BE INTERESTED IN

After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities. 

Login